{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:42:44Z","timestamp":1793720564643,"version":"4.6.1"},"reference-count":25,"publisher":"Japanese Society of Internal Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018]]},"DOI":"10.2169\/internalmedicine.8335-16","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T18:12:12Z","timestamp":1509473532000},"page":"387-391","source":"Crossref","is-referenced-by-count":15,"title":["The Serum Ferritin Level Is Associated with the Treatment Responsivity for Rapidly Progressive Interstitial Lung Disease with Amyopathic Dermatomyositis, Irrespective of the Anti-MDA5 Antibody Level"],"prefix":"10.2169","volume":"57","author":[{"given":"Takeshi","family":"Osawa","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"},{"name":"Division of Clinical Research, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Yamana","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryozo","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Uchiyama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46: 626-636, 2002.","DOI":"10.1067\/mjd.2002.120621"},{"key":"2","unstructured":"2. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 54: 597-613, 2006."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sato S, Kuwana M. Clinically amyopathic dermatomyositis. Curr Opin Rheumatol 22: 639-643, 2010.","DOI":"10.1097\/BOR.0b013e32833f1987"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Fujisawa T, Hozumi H, Kono M, et al. Prognostic factors for myositis-associated interstitial lung disease. PLoS One 9: e98824, 2014.","DOI":"10.1371\/journal.pone.0098824"},{"key":"5","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1378\/chest.13-0186","volume":"144","author":"A Teruya","year":"2013","unstructured":"5. Teruya A, Kawamura K, Ichikado K, Sato S, Yasuda Y, Yoshioka M. Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140\/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis. Chest 144: 1934-1936, 2013.","journal-title":"Chest","ISSN":"https:\/\/id.crossref.org\/issn\/0012-3692","issn-type":"print"},{"key":"6","unstructured":"6. Ichiyasu H, Horio Y, Tsumura S, et al. Favorable outcome with hemoperfusion of polymyxin B-immobilized fiber column for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis: report of three cases. Mod Rheumatol 24: 361-365, 2014."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Gono T, Kawaguchi Y, Hara M, et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 49: 1354-1360, 2010.","DOI":"10.1093\/rheumatology\/keq073"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Gono T, Kawaguchi Y, Satoh T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 49: 1713-1719, 2010.","DOI":"10.1093\/rheumatology\/keq149"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford) 51: 1563-1570, 2012.","DOI":"10.1093\/rheumatology\/kes102"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gono T, Kawaguchi Y, Ozeki E, et al. Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol 21: 223-227, 2011.","DOI":"10.3109\/s10165-010-0371-x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tamai K, Tachikawa R, Otsuka K, Ueda H, Hosono Y, Tomii K. Early pulmonary involvement of anti-CADM-140 autoantibody-positive rapidly progressive interstitial lung disease preceding typical cutaneous symptoms. Intern Med 53: 2515-2519, 2014.","DOI":"10.2169\/internalmedicine.53.2769"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52: 1571-1576, 2005.","DOI":"10.1002\/art.21023"},{"key":"13","unstructured":"13. Ichiyasu H, Sakamoto Y, Yoshida C, et al. Rapidly progressive interstitial lung disease due to anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis complicated with cervical cancer: successful treatment with direct hemoperfusion using polymyxin B-immobilized fiber column therapy. Respir Med Case Rep 20: 51-54, 2017."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sato S, Kuwana M, Fujita T, Suzuki Y. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140\/MDA5 autoantibodies. Mod Rheumatol 22: 625-629, 2012.","DOI":"10.3109\/s10165-011-0558-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yamaguchi K, Yamaguchi A, Uchida M, et al. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol 27: 536-540, 2017.","DOI":"10.3109\/14397595.2015.1014140"},{"key":"16","unstructured":"16. Horai Y, Isomoto E, Koga T, et al. Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases. Mod Rheumatol 23: 190-194, 2013."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Zou J, Li T, Huang X, Chen S, Guo Q, Bao C. Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody. Ann Rheum Dis 73: 1591-1593, 2014.","DOI":"10.1136\/annrheumdis-2014-205278"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yamaoka T, Doi C, Yokomi A, et al. Anti-MDA5 antibody-positive dermatomyositis with lethal progressive interstitial lung disease and advanced gastric cancer. Eur J Dermatol 24: 490-491, 2014.","DOI":"10.1684\/ejd.2014.2381"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 23: 496-502, 2013.","DOI":"10.3109\/s10165-012-0663-4"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM\/interstitial lung disease during disease remission. Rheumatology (Oxford) 51: 800-804, 2012.","DOI":"10.1093\/rheumatology\/ker408"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Matsushita T, Mizumaki K, Kano M, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol 176: 395-402, 2017.","DOI":"10.1111\/bjd.14882"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Nakashima R, Mimori T. [Anti-MDA5 antibody and dermatomyositis with rapidly progressive interstitial pneumonia]. Nihon Rinsho Meneki Gakkai Kaishi (Jpn J Clin Immunol) 36: 71-76, 2013 (in Japanese, Abstract in English).","DOI":"10.2177\/jsci.36.71"},{"key":"23","unstructured":"23. Abe S, Seo Y, Hayashi H, et al. Neutrophil adsorption by polymyxin B-immobilized fiber column for acute exacerbation in patients with interstitial pneumonia: a pilot study. Blood Purif 29: 321-326, 2010."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Abe S, Hayashi H, Seo Y, et al. Reduction in Serum High Mobility Group Box-1 level by polymyxin B-immobilized fiber column in patients with idiopathic pulmonary fibrosis with acute exacerbation. Blood Purif 32: 310-316, 2011.","DOI":"10.1159\/000330325"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Oishi K, Mimura-Kimura Y, Miyasho T, et al. Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis. Cytokine 61: 84-89, 2013.","DOI":"10.1016\/j.cyto.2012.08.032"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/3\/57_8335-16\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T07:47:49Z","timestamp":1570261669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/3\/57_8335-16\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8335-16","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}